The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's.
ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.
The new guideline calls for a “stepwise approach," followed by close clinical surveillance, when treating uncomplicated TBAD. In some cases, however, earlier endovascular treatments may be necessary.
Artificial intelligence also played a large role in discovering how this intricate network of muscle fibers can influence health, experts explained in Nature.
